Overview
Tasuku Honjo practices practicing medicine in Kyoto, Japan.
Their clinical expertise encompasses Immunodeficiency with Hyper IgM Type 1, Ovarian Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer.
They are actively involved in clinical research, co-authoring 86 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Tasuku Honjo
Is Tasuku Honjo a top-rated expert for Immunodeficiency with Hyper IgM Type 1?
MediFind is an objective health platform that identifies experts based on real-world data. Tasuku Honjo is classified as an Experienced expert for Immunodeficiency with Hyper IgM Type 1, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Tasuku Honjo participate in research or clinical trials?
Yes. Tasuku Honjo has published 86 articles and abstracts on conditions like Immunodeficiency with Hyper IgM Type 1. You can view a list of Tasuku Honjo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Immunodeficiency with Hyper IgM Type 1
- Lung CancerHonjo isExperienced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Ovarian CancerHonjo isExperienced. Learn about Ovarian Cancer.